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Abstract: Rhodiola rosea (Rro) has been reported to have various pharmacological 
properties, including anti-fatigue, anti-stress and anti-inflammatory activity. It is also 
known to improve glucose and lipid metabolism, but the effects of Rhodiola rosea on 
adipocyte differentiation and metabolism are not still elucidated. In this study the  
anti-adipogenic and lipolytic activity of two extracts of Rhodiola rosea, containing 3% 
salidroside (RS) or 1% salidroside and 3% rosavines (RR) on primary human visceral 
adipocytes was investigated. Pre-adipocytes were analyzed after 10 and 20 days of 
treatment during differentiation and after 7 days of treatment when they reached mature 
shape. The RS extract significantly induced higher apoptosis and lipolysis in comparison to 
control cells and to RR extract. In contrast, RR extract significantly reduced triglyceride 
incorporation during maturation. Differentiation of pre-adipocytes in the presence of RS and 
RR extracts showed a significant decrease in expression of genes involved in adipocyte 
function such as SLC2A4 and the adipogenic factor FGF2 and significant increase in 
expression of genes involved in inhibition of adipogenesis, such as GATA3, WNT3A, 
WNT10B. Furthermore RR extract, in contrast to RS, significantly down-regulates 
PPARG, the master regulator of adipogenesis and FABP4. These data support the lipolytic 
and anti-adipogenetic activity of two different commercial extracts of Rhodiola rosea in 
primary human visceral pre-adipocytes during differentiation. 
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1. Introduction 
Many natural phytonutrients have been recognized to have beneficial effects on health and several 
botanicals have received positive attention for their antiadipogenic and metabolic effects in animals 
and humans [1,2]. The increase of body fat is due to an imbalance between energy intake and energy 
expenditure and natural products can be useful to decrease lipid absorption, energy intake, lipogenesis, 
pre-adipocyte differentiation and proliferation, or to increase energy expenditure and lipolysis [3,4]. 
These properties are reported for specific flavonoids [5], such as chlorogenic acid from green coffee 
bean [6] and carnosic acid in rosemary [7,8]. Among the plants with favorable bioactivity on fat tissue 
and metabolism, Rhodiola rosea (Rro), a popular plant in the Nordic countries, Eastern Europe and 
Asia, has gained attention in the past and its liquid extract has been produced industrially in Russia 
since 1975 [9]. More recently, Rro was registered in the UK as a traditional herbal medicinal product for 
use as anadaptogen [10]. The Rro belongs to the family of Crassulaceae, genus Rhodiola, and includes 
more than 100 different species, at least 20 of which are used in traditional Asian medicine [11,12]. 
However, animal and human studies have been conducted on Rro, so whether other species confer the 
same health benefits is unknown [13,14]. 
Phytochemical studies on the Rro root have shown the presence of six groups of compounds: 
phenylpropanoids (rosin, rosavin, rosarin), phenylethanol derivatives (salidroside, tyrosol), flavonoids 
(acetylrodalgin, rodiolin, rodionin, rodiosin, tricin), monoterpernes (rosaridin, rosiridol), triterpenes  
(β-sitosterol, daucosterol) and phenolic acids (chlorogenic hydroxycinnamic and gallic acids) [15,16]. 
According to the Soviet Pharmacopeia [17], the extracts of Rro are standardized for both rosavins and 
salidroside (p-hydroxyphenylethyl-O-β-D-glucopyranoside). Rro extracts used in human clinical 
studies are often standardized to minimum 3% rosavins and 0.8%–1% salidroside, because the ratio of 
these compounds in Rro root is approximately 3:1 [14]. Although Brown et al. [11] considered that 
standardized Rro extract should contain the full spectrum of pharmacologically active compounds, 
including not only salidroside and p-tyrosol, but also rosavin, rosin, and rosarin, many suppliers have 
only standardized their products to 1% salidroside. Meanwhile, according to Chang et al. [18], 
salidroside is considered to be one of the major phenolic glycosides in Rro, and is generally used to 
evaluate the quality of Rhodiola. 
The main effect described of genus Rhodiola is adaptogenic, meaning that in normal doses the 
products are non-toxic, produce a non-specific response and have a normalizing physiologic influence 
and stress protective activity [14]. Rro is mainly known for stimulating physical endurance, attention 
span, memory, and work productivity [19–21], whereas its bioactivity on adipocytes is poorly 
characterized. Apart the known antioxidant [22–24], antitumour [25,26], antidepressive [27,28], 
neuroprotective [29,30], cardioprotective [31,32] hepatoprotective [33,34], and immunostimulating 
effects [35–37], Rro has been recently described for its ability to regulate blood sugar levels in 
diabetics and to activate the lipolytic processes [38,39]. Moreover, Rro standardized for 3% rosavins 
and 1% salidroside, in combination with Citrus aurantium, has been indicated to mobilize lipids from 
adipose tissue for weight reduction [40]. Rro plus Citrus aurantium has been found to decrease visceral 
fat weight by 30% of rats fed with high fat diet, having a direct effect on sympathetic tone and on 
hypothalamic norepinephrine secretion [40]. Ethanol soluble fraction of Rro, not clearly characterized 
for its content, has been demonstrated to induce peroxisome proliferator-activated receptor delta (PPARδ) 
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expression in cardiomyocytes [32]. PPARδ is a homologue of PPARγ, and plays an important role in 
many tissues such as brain, skin, muscles and adipocytes [41]. Peroxisome proliferator-activated 
receptor beta (PPARβ) and PPARδ prevent triglyceride accumulation and increases lipid catabolism in 
adipocytes [42]. In addition, PPARδ increases thermogenesis by up-regulation of the expression of 
hormone-sensitive lipase (HSL) and uncoupling protein 1 (UCP1) [42,43]. If the action of Rro on 
PPARβ/δ expression in adipocytes corresponded to that in cardiomyocytes, a reduction of lipogenesis 
and an increase of lipolysis could be expected also in adipose tissue cells. 
In a recent paper, El-Houri et al. [44] have reported that only the dichloromethane extract of aerial 
parts of Rro, but not methanol extract, triggered PPARG transactivation without stimulating adipocyte 
differentiation. Conversely, either dichloromethane or methanol root extracts inhibited fat accumulation 
in the C. elegans model. The type of solvent and the extraction procedures applied to root or aerial 
parts produce extracts of variable composition and consequently with diverse bioactivities [44]. 
Clinical trials performed in the Russian Federation have provided interesting evidence such as the 
fact oral administration of 200 mg Rro extract with rosavin activates HSL and mobilizes fatty acids 
from adipose tissue in healthy volunteers and obese patients [45,46]. Moreover, it has been 
demonstrated that rosiridin, a bio-active compound isolated from Rro, interferes with the degradation 
of norepinephrine that regulates the HSL activity by inhibiting the action of monoamine oxidases 
(MAOs) [47] and breaks down fat stored in adipose tissue. 
Evaluating the present knowledge, this interesting adaptogenic plant could be useful to reduce or 
prevent adipogenesis and to support weight loss. However in vitro scientific research at the cellular 
and molecular levels are required to explain and to confirm the benefits of Rro on lipid metabolism and 
adipogenesis. Considering the different spectra of extracts contained in Rhodiola preparations, the 
present research aims to identify possible effects on primary human omental pre-adipocytes and 
mature adipocytes. Moreover, two different extracts, one (RS) standardized for salidroside (≥3%) and 
the other (RR) standardized for salidroside (≥1%) and rosavines (≥3%) were compared. In particular, 
the effects of RS and RR extracts were tested in vitro on pre-adipocyte and adipocyte viability, 
apoptosis, lipolysis and adipogenesis. In addition, expression levels of genes involved in the human 
adipogenesis pathway during pre-adipocyte differentiation were analyzed by PCR array. 
2. Results and Discussion 
2.1. Cell Viability 
A viability assay was used to find out the highest dose of RR and RS extracts that allowed a cell 
viability over 60%. After treating P10, P20 and A7 cells with 5, 10, 30 or 70 µg/mL RR and RS 
extracts, the data showed that cell viability on P10 and P20 cells significantly (p < 0.001) decreased in 
a dose-dependent manner (Table 1), and that the viability measured at a dose of 70 µg/mL was always 
significantly different from other doses. Nevertheless, viability of all cells except A7 remained over 
60% up to 30 µg/mL dose and markedly decreased at 70 µg/mL. In A7 cells viability remained over 
80% up to 70 µg/mL dose. According to these evidences, 30 µg/mL of plant extract was chosen for  
the experiments. 
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Table 1. Modulation of MTT metabolism by RS or RR extracts in human omental  
pre-adipocytes. Cells were treated with different doses of extracts. P10 differentiating  
pre-adipocytes treated for 10 days; P20 differentiating pre-adipocytes treated for 20 days; 
A7, mature adipocytes treated for 7 days. Data are expressed as percentage of control cells 
(untreated) and presented as means ± standard deviation (SD). Different superscript capital 
letters indicate significant differences (p < 0.001) within treatments at different concentrations.  
Dose 
(µg/mL) 
P10 P20 A7 
RS RR RS RR RS RR 
5 91.83 A ± 7.55 91.51 A ± 7.58 91.34 A ± 3.26 89.41 A ± 3.42 96.32 A ± 1.71 96.74 A ± 1.83 
10 80.26 B ± 6.84 80.17 B ± 7.01 78.52 B ± 2.43 79.02 B ± 3.13 95.81 A ± 2.05 96.29 A ± 1.92 
30 76.75 C ± 6.43 79.95 B ± 6.78 66.85 C ± 2.88 67.77 C ± 3.33 96.09 A ± 2.25 93.84 A ± 2.25 
70 53.58 D ± 7.15 55.30 C ± 4.23 36.26 D ± 2.06 42.28 D ± 4.33 89.81 B ± 1.91 84.34 B ± 3.06 
2.1.1. RR and RS Extracts Decrease Triglyceride Accumulation 
The ability of RS and RR extracts to prevent triglyceride accumulation was demonstrated on P10 
and P20 cells treated with 30 µg/mL extracts and on the corresponding CTRL cells. The total amount 
of lipid accumulation was reported as a percentage respect to CTRL (where CTRL was considered as 
100%, Figure 1).  
 
Figure 1. Effects of RS and RR extracts on triglyceride accumulation during pre-adipocyte 
differentiation. Triglyceride accumulation of differentiating pre-adipocytes incubated for 
10 d (P10) and 20 d (P20) with RS and RR extracts relative to untreated control cells 
(CTRL) set as 100%. Results are depicted as mean ± standard deviation (SD). Asterisks ** 
indicate the significant difference between treatments for p < 0.001.  
The data indicate that the tested compounds, compared to CTRL, inhibit adipogenesis at P10 and 
P20, exhibiting a significant (p < 0.001) decrease of triglyceride levels compared to CTRL. 
Triglyceride accumulation was significantly (p < 0.001) lower in cells treated with RR (68.08 ± 14.27 
at P10 and 24.99 ± 6.91 at P20), in comparison to cells treated with RS (80.77 ± 17.91 at P10 and 
37.80 ± 17.27 at P20). The interaction between cells at different stages and treatments was also 
significant (p < 0.001). 
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2.1.2. RR and RS Extracts Increase Glycerol Release 
The lipolysis activity was assessed on P20 and A7 cells treated with 30 µg/mL RR and RS extracts 
and on the corresponding CTRL cells. Treatment of P20 cells with RS extract significantly (p < 0.001) 
incremented the content of free glycerol in the culture medium to 175.47 μM (±41.3) as compared to 
117.31 μM (±5.6) in RR-treated cells and 90.7 μM (±3.9) in CTRL cells (Figure 2). On the contrary, 
the treatment of A7 cells with RR extract significantly (p < 0.001) increased the release of free 
glycerol to 96.8 μM (±14.7) in comparison to RS-treated cells (91.5 μM (±10.5)) and to CTRL cells 
(2.9 μM (±0.7)) (Figure 2). The interaction between cells at different stages and treatments was also 
significant (p < 0.001). 
 
Figure 2. Determination of glycerol release in differentiating (P20) and mature (A7) 
adipocytes after incubation with RS and RR extracts where glycerol content is given in μM. 
Results are depicted as mean ± standard deviation (SD). Asterisks ** indicate the 
significant difference between treatments for p < 0.001. 
2.1.3. Effect of RR and RS on Apoptosis 
The apoptotic effect of the extracts was examined on P10, P20 and A7 cells treated with 30 µg/mL 
RS and RR and on corresponding CTRL cells. A significant (p < 0.001) increase of the percentage of 
apoptosis in P10 and P20 cells under treatment with RR and RS extracts was observed (Figure 3).  
On the contrary, the apoptotic percentage on A7 cells did not significantly vary between treatments. 
The interaction between cells at different stages and treatments was also significant (p < 0.001). 
Interestingly, the percentage of apoptosis induced by RS extract (64.84% ± 8.81% at P10 and 68.61% 
± 4.17% at P20) was significantly (p < 0.001) higher than that induced by RR extract (51.25% ± 3.85% 
at P10 and 59.98% ± 1.98% at P20). 
Morphological characteristics of P20 cells, labelled by TUNEL assay, are shown in Figure 4. Nuclei 
of apoptotic cells were marked in brown colour and showed chromatin condensation with a diffuse 
increase in nuclear density and parallel loss of nuclear volume (Figure 4A,C). These features were 
followed by fragmentation of cell and its nucleus, resulting in smaller apoptotic bodies (Figure 4B). 
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Figure 3. Modulation of apoptosis by RS and RR extracts in human omental  
pre-adipocytes. Cells were treated with 30 µg/mL RR and RS extracts. P10, differentiating 
pre-adipoctes treated for 10 d; P20, differentiating pre-adipocytes treated for 20 d; A7, 
mature adipocytes treated for 7 d. Data are presented as mean ± standard deviation (SD). 
Asterisks ** indicate the significant difference between treatments for p < 0.001 as 
percentage vs positive CTRL. 
 
Figure 4. Cytological visualization of apoptosis by TUNEL assay on P20 pre-adipocytes. 
Nuclei of apoptotic cells are marked in brown, counterstained with Gill’s hematoxylin.  
(A) CTRL cells; the nuclei are clearly positive, partly demonstrating alteration of nuclear 
membrane; (B) RS-treated pre-adipocytes; extrusion of apoptotic nucleus, presence of 
apoptotic bodies and nucleus fragmentation; (C) RR-treated pre-adipocytes; positive nuclei 
with condensed chromatin and apoptotic remnants. 
2.1.4. Effects of RR and RS Extracts on the Level of Expression of Adipogenesis-Associated Genes 
The expression pattern of genes involved in the adipogenesis pathways was measured on P20 
treated cells using a human RT2 Profiler PCR Array. Volcano plot reported the log2(n-fold) values of 
significantly (p < 0.05) up- and down-regulated genes in comparison to CTRL cells (Figure 5). The 
results revealed that RS extract modulates the expression of 13% (11/84) of the genes (Figure 5A) and 
RR extract modulates the expression of 50% (42/84) of the genes (Figure 5B). 
Molecules 2015, 20 8415 
 
 
 
Figure 5. Volcano plot of adipogenesis PCR array. PCR array analysis of gene expression 
in RS and RR-treated P20 cells in comparison to P20 CTRL cells. (A) Gene expression of 
P20 RS-treated cells. (B) Gene expression of P20 RR-treated cells. Total RNA from three 
independent experiments, one per each donor, was isolated from both CTRL cells and cells 
treated with RR or RS extracts incubation. Cells were used at the third passage. The 
relative expression levels for each gene depicted as log2(n-fold) are plotted against  
−Log(p-value). Red indicator = significantly up-regulated gene; Green indicator = 
significantly down-regulated gene. Red line indicates −Log(p-value), p < 0.05.  
Among the genes involved in the adipogenesis, CAMP responsive element binding protein 1 (CREB1), 
peroxisome proliferator-activated receptor, gamma 2 (PPARG), fibroblast growth factor 2 (FGF2), 
retinoblastoma 1 (RB1), CCAAT/enhancer binding protein, delta (CEBPD), cyclin D1 (CCND1), 
solute carrier family 2, member 4 (SLC2A4), sirtuin 3 (SIRT3), secreted frizzled-related protein 1 
(SFRP1) and fatty acid binding protein 4 (FABP4) were significantly (p < 0.05) down-regulated from 
RR extract (30 μg/mL). Among the genes involved in inhibition of adipogenesis, delta-like 1 homolog 
(DLK1), GATA binding protein 2 (GATA2), GATA binding protein 3 (GATA3), Kruppel-like factor 2 
(KLF2), wingless-related MMTV integration site 10B (WNT10B), wingless-related MMTV 
integration site 3A (WNT3A), sonic hedgehog (SHH), adrenoceptor beta 2 (ADRB2) and tafazzin 
(TAZ) were significantly (p < 0.05) up-regulated. 
Treatment with RS extract (30 µg/mL) up-regulated (p < 0.05) the expression of wingless-type MMTV 
integration site family, member 1 (WNT1) and of the genes which were similarly modulated by RR 
extract (WNT5B, KLF15, FGF10, SFRP5, EGR2, NR0B2, BMP7), one of which, GATA2 (GATA 
binding protein 2), involved in inhibition of adipogenesis. The expression of FGF2 and FABP4 
involved in inhibiting adipogenesis, significantly (p < 0.05) decreased also in RS-treated cells. 
2.2. Discussion 
Adipogenesis is a cell differentiation regulated by a profusion of transcription factors and cell-cycle 
proteins that regulate gene expression and lead to mature adipocytes. In this network regulators that 
activate or inhibit the transformation of cells from fibroblastic to spherical shape are involved [48]. 
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The obesity is thus related to an increase of number and size of adipocytes that takes place in 
association with positive energy balance. 
Research in nutrition to find natural products that, targeting adipocytes and their pathways, could lead 
to induction of lipolysis and apoptosis or to inhibition of adipogenesis has been recently aroused [4,8]. 
Given the numerous effects of Rro, including the influence on feeding behavior [49], and the different 
available content of bioactive compounds, one of the objectives of the present study was to compare 
the effects of two different extracts of Rro in preventing adipogenesis and in modifying adipose cells 
metabolism on human primary visceral adipocytes. 
The ability of RS and RR extract to prevent lipid accumulation was examined with Oil Red O 
staining and triglyceride content on P10 and P20 human primary omental pre-adipocytes. The 
reduction of triglyceride incorporation during differentiation of RS and RR treated cells (Figure 1) was 
coincident with an enhancement of lipolytic activity, as detected by an increase of glycerol release, in 
P20 RS-treated cells and in A7 RR-treated adipocytes (Figure 2). Lipolytic activity has been reported 
to rosavines, cynnamic glycosides [50], that are demonstrated to stimulate lipoprotein lipase (LPL). 
However, it should be noted that RS extract was significantly (p < 0.001) more effective than RR 
extract in inducing apoptosis both on P10 and P20 cells, whereas the treatment of A7 adipocytes did 
not lead to any difference in comparison to CRTL cells (Figure 3). The lack of response of mature 
adipocytes (A7) to cell viability treatments (Table 1) corresponds to previous observations on mature 
human adipocytes exposed to Rosmarinus officinalis extract [8]. Studies on animal, conducted with  
R. crenulata standardized for 1.1% salidroside, p-tyrosol (0.3183%), trans-caffeic acid (0.036%) and 
kenposide A (0.0195%), have been reported to improve glucose and lipid metabolic disturbance in 
Zucker diabetic fatty (ZDF) rats [51]. Although a detailed molecular mechanism of the lipid lowering 
and anti-inflammation effects of  salidroside alone has not yet been identified, in vivo studies on high 
fat diet-fed LDLr−/− mice demonstrated that this compound reduced serum lipid levels and decreased 
atherosclerotic plaque formation [52]. The hypolipidemic activity of Rro in Winstar rats fed with 
hypercholesterolemic diet was also reported [53]. In fact, RS extract significantly affected lipolysis and 
apoptosis in comparison to RR extract that was more effective in reducing differentiation. This 
distinctive bioactivity of two extracts can be due to the lower concentration of salidroside in RR or due 
to the different composition of its phytocomplex that contains also rosavines and therefore deserves 
further studies. A different modulation of gene expression in adipogenesis-related genes between 
extracts was also found during differentiation of pre-adipocytes (P20) (Figure 5 and SM Table 1). 
To date, only one paper reported the effect of salidroside on the differentiation of 3T3-L1 adipocytes, 
using in this biological research the mouse embryonic fibroblast cell line [54]. In this cell line, salidroside 
promoted the 3H-glucose uptake, significantly suppressed the differentiation, down-regulated the 
expression of peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT-enhancer-binding 
proteins alpha (C/EBPα) mRNA [54]. Interestingly, salidroside has been proven to have curative 
proprieties in bingeing-related eating disorders in rat models [55]. Since binge eating was evoked by 
combining stress and repeated episodes of food restriction, the effects of salidroside on this 
experimental model could be considered as an indirect approach to treat the energy intake. 
Genes that inhibit the pre-adipocyte to adipocyte transition, including members of the GATA-binding 
proteins and WNT family of secreted glycoproteins, were significantly (p < 0.05) up-regulated in P20 
treated cells. It is known that continuous expression of the binding proteins GATA2 and GATA3 can 
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inhibit the differentiation in pre-adipocytes [56]. The enhanced expression of GATA2 and GATA3 
suppresses adipocyte differentiation through the reduced PPARG and CEBPs activity [57]. The in vitro 
data revealed that both extracts up-regulate the GATA2 expression and RR extract affects also the 
expression of GATA3 (Figure 5). It has been observed that berberine and evodiamine, two botanical 
alkaloids [58], and also rosemary extract [8] up-regulate the expression of GATAs and influence the 
PPARG and CEBPA expression. Therefore, the expression of GATAs may contribute to the observed 
down-regulation of PPARG. Moreover, in P20 RR-treated cells the repression of PPARG may be 
mediated by the over-expression of KLF2, has been also recognized as anti-adipogenetic factor, 
repressing PPARG promoter [59]. This was also observed for yerba maté and resveratrol on 3T3-L1 
cell line [60]. However, in both P20 RR- and RS-treated cells, KLF15, which promotes adipocytes 
differentiation and is induced in the early stages of adipocyte differentiation [61] was significantly  
up-regulated. In the present study, KLF15 was not activated by CEBPB and CEBPD, which was 
significantly down-regulated in RR-treated cells (Figure 5 and SM Table1). The results obtained for 
RR-treated cells are in the agreement with the loss of SLC2A4 expression, that is usually a target of 
KLF15 [62]. 
In addition, it is known that the CEBPs and PPARG expression depends on DLK1, also known as 
preadipocyte factor 1 (Pref-1), and it is widely accepted that DLK1 plays an important role in adipocytes 
differentiation [63]. Gene expression analysis of P20 RR-treated cells showed over-expression of DLK1 
as well as up-regulation of the transcriptional co-activator with PDZ-binding motif (TAZ), known as 
co-repressor of PPARG in adipose tissue. The observed down-regulation of PPARG and CEBPD led to 
a reduced expression of key genes involved in downstream differentiation (FABP4, SLC2A4), and 
induced phenotypic changes as triglyceride accumulation. 
Wnts are a broad family of proteins that participate in several cellular biological processes, and it is 
reported that Wnt signaling has a role in preventing adipocyte differentiation [64]. WNT6, WNT10A, 
and WNT10B are expressed in precursor cells and decline during differentiation blocking adipogenic 
conversion of 3T3-L1 pre-adipocytes through stabilization of β-catenin and inhibition of CEBPA and 
PPARG [65]. In contrast, WNT5B and WNT4 are transiently induced during adipogenesis and act to 
promote this process [66]. A further research suggests that, in order to elicit its antiadipogenic effects, 
the canonical ligand WNT3A among several others inhibits activation of both PPARG and CEBPA [67]. 
As recently observed, WNT3A, an inhibitor of pre-adipocyte to adipocyte transition, was significantly 
up-regulated in human pre-adipocytes treated with Rosmarinus officinalis extract [8] and in 3T3-L1 
cells treated with herba maté [68]. In our study a significant increase in the expression of WNT3A, 
WNT10B, WNT5B was observed in P20 RR-treated cells in comparison to CTRL cells. In P20 RS-treated 
cells WNT1, WNT10B, WNT5B were significantly up-regulated as well. In particular, WNT1 was  
up-regulated only by RS extract and WNT10B, WNT5B were respectively up-regulated 3- and 2-fold 
in comparison to RR treated cells. These results may be of interest since it has been demonstrated that 
WNT10B mutations are associated with obesity [69] and that it blocks adipogenesis in 3T3-L1 
preadipocytes in vitro via stabilization of free cystolic β-catenin [70]. Moreover, WNT1 has been 
recently recognized as an adipokine and a possible novel therapeutic target for obesity linking obesity 
to inflammation and insulin resistance [71]. 
WNT5B is known to promote adipogenesis in 3T3-L1 preadipocytes, inhibiting canonical Wnt/ 
β-catenin signaling pathway and stimulating PPARG and FABP4 [72,73]. In P20 treated cells, the  
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up-regulation of WNT5B did not induce PPARG nor FABP4 expression, but it is likely that the 
decreased expression of CCND1, which is a downstream target gene of β-catenin [74], can be related 
to impaired canonical Wnt pathway. Indeed even SFRPB5 and DKK1, known as Wnt pathways 
inhibitors, were up-regulated by RR treatment and only SFRPB5 by RS treatment. Meanwhile, 
SFRPB1 was significantly down-regulated by RR extract. Interestingly, the relationship between 
WNT5A and SFRPB5 shows some intriguing controversies. The role of SFRP5 remains unclear 
because it has been shown that SFRP5 was up-regulated [61] and down-regulated [75] in WAT of 
different obese mouse models. Furthermore, SFRP5−/− mice are reported to be either resistant [61] or 
sensitive [75] to diet induced obesity. In addition, in human visceral adipocytes it has been 
demonstrated that SFRP5, binding and isolating WNT5A, prevents activation of frizzled receptors thus 
attenuating the noncanonical Wnt signaling [76]. In cells treated with RS extract, we observed an  
up-regulation of SFRP5 and a down-regulation of WNT5A and it can be speculated that the balance 
between WNT5A and SFRP5 expressions may act as a rheostat to control the degree of noncanonical 
Wnt signaling. 
Transcription of genes involved in re-entry to the cell cycle of pre-adipocytes is known to be  
under regulation of a cascade of cell-cycle proteins such as Cdk-cyclin-E2F-Rb signaling family 
members [77,78]. The retinoblastoma proteins (pRb) regulate the activity of E2F transcription factors 
and E2F1 is strongly upregulated during the first phases of adipogenesis, when it regulates adipocyte 
differentiation, modulating the expression of genes such as PPARG and CCND1. In the present study, 
RR extract entailed an up-regulation of E2F1, but a down-regulation of upstream (RB1) and 
downstream targets (PPARG, CCND1). In fact, it is know that pRb can also act negatively during 
adipogenesis by forming a complex with PPARG [79]. Moreover, it is known that D-type cyclins 
represent a link between cell cycle progression, cell differentiation, and transcriptional regulation, 
being CCND1 repressor of PPARG expression and CCND3 activator of master regulator [80]. 
3. Experimental Section 
3.1. Materials 
Two extracts of Rhodiola rosea root of Chinese origin, were provided by the company nVH Italia 
(Cadorago, Italy) and according to the technical sheet one contained only salidroside (≥3%) (named 
here RS) and the other contained salidroside (≥1%) and cinnamylglycosides (rosavines) (≥3%) (named 
here RR). To obtain RS and RR extracts, Rhodiola root was dissolved in 70/30 (V/V) and 60/40 (V/V) 
water/ethanol solution, respectively, at 105 °C for 3 h, then the extract solution was centrifuged and the 
upper liquid was lyophilized, whereby the loss on drying was <5%. The drug extract ratio was 10:1 for 
RS and 6/8:1 for RR. 
In the RR phytocomplex, but not in the RS, rosarin, rodosin, rosin, gallic acid, caffeic acid and 
chlorogenic acid were also present in unspecified amounts. 
The dried extracts were stored in refrigerator at 2–8 °C until use. For further analyses then each 
extract (50 mg) was dissolved in 1 mL of water solution of 10% dimethylsulfoxide (DMSO), filtered 
with 0.22 µm pore size (Millipore, Milan, Italy) and kept in the dark at −20 °C. 
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3.2. Cell Culture and Cell Treatment 
Cells and media were obtained from Zen-Bio (Research Triangle Park, NC, USA). Primary omental 
pre-adipocytes were collected from Caucasian normal (non-diabetic and non-smoker) women donors 
(n = 3). The mean donor age was 48.67 ± 9.07 year and mean BMI was 42.70 ± 6.95 kg/m2.  
Pre-adipocytes were cultured in omental pre-adipocytes medium (OM-PM). In order to differentiate 
pre-adipocytes into adipocytes, omental differentiation medium (OM-DM) was used. Differentiated 
adipocytes were cultured in omental adipocyte maintenance medium (OM-AM). All cells were 
maintained in humidified air with 5% CO2 at 37 °C [8]. 
Cells (passage 3) were treated with RR and RS extracts at increasing concentrations and during 
different stages of differentiation with the same final concentration of 0.014% DMSO in the culture 
medium. The control cells (CTRL) were incubated within the same conditions at final concentration of 
DMSO 0.014% in culture medium. Treatments were performed in three different stages of the cell life 
cycle: on pre-adipocytes for 10 days (P10) and 20 days (P20) in OM-DM, and on mature fully 
differentiated adipocytes for 7 days (A7) in OM-AM. 
For the apoptosis, lipolysis and adipogenesis assays, cells were seeded in a 96 well plate at a density 
of 1 × 104 cells/well. For PCR assay, cells were seeded in a 6 well plate at a density of 1 × 105 cells/well 
and left to grow overnight. The analysis was performed using cells of the three different donors and 
each donor was assayed in triplicate. 
3.2.1. Cell Viability 
The effect of the RS and RR extracts at different concentrations (0, 5, 10, 30 and 70 µg/mL) on cell 
viability was determined by a colorimetric assay in P10, P20 and A7 cells based on 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) [81]. For the MTT assay, cells were 
seeded in a 96 well plate at a density of 1 × 104 cells/well then cells were washed with 1X PBS and 
fresh medium with 20 μL of MTT reagent (5 mg/mL) (Sigma, Milan, Italy) was added to each well, 
followed by 3 h incubation at 37 °C. After, the mixture was suctioned completely and 100 μL/well of 
DMSO was added to dissolve the formed formazan crystals. The absorbance was measured at 570 nm 
by a microplate reader and the surviving cell fraction was calculated. The cell viability was expressed 
as a percentage relative to CTRL cells considered as 100%. 
3.2.2. Oil Red O Staining and Measurement of Lipid Accumulation 
In order to quantify lipid accumulation, Oil-Red O staining (ORO, Sigma) was used. The assay was 
performed on treated and CTRL P10 and P20 cells. After treatment with RR and RS extract (30 μg/mL) 
on 96 well culture plate, cells were first rinsed with PBS and then fixed with 4% formaldehyde for  
30 min. Cells were stained with the ORO working solution (40% of ORO staining and 60% of milliQ 
water) for 20 min at 25 °C and examined by an optical microscope (PrimoVert, Zeiss, Jena Germany) 
to evaluate lipid accumulation. Lipids were extracted from the cells using DMSO and quantified with a 
microplate reader at 510 nm. Data were expressed as percentage of triglyceride accumulation vs. CTRL. 
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3.2.3. Lipolysis Assay 
Lipolytic activity was detected with AdipoLyzeTM Lipolysis Detection Kit (Lonza Inc., 
Walkersville, MD, USA) according to provider’s instructions. Using a fluorescent kit designed to 
quantify the glycerol released by cells undergoing lipolysis, the glycerol detection was performed on 
P20 and A7 cells. An amount of 50 μL of the culture medium supplemented with RR or RS extract was 
removed from each well and added to a new 96 well plate. Enzyme/detection solution (50 μL) was 
added in each well followed by further incubation for 1 h in dark. Finally, fluorescence was measured 
at 570 nm excitation and 595 nm emission wavelength by a fluorescent microplate reader. Orbital 
shaking for 5 s was applied before measurement. Data were compared with a standard curve of 
fluorescence obtained from measurements of standard glycerol from 0.0 μM to 108.6 μM. 
3.2.4. Apoptosis Assay 
Detection of apoptotic cells was done using ApoStrandTM ELISA apoptosis detection kit (Enzo Life 
Sciences Inc., Farmingdale, NY, USA) was used according to the provider’s instructions. This assay is 
based on the denaturation of DNA in apoptotic cells by formamide, which reproduces changes in 
chromatin related to apoptosis. Further the denatured DNA is revealed with a mixture of primary 
antibody and peroxidase-labeled secondary antibody. P10, P20 and A7 RR and RS-treated cells  
(30 µg/mL) were fixed for 30 min and dried in an oven at 56 °C for 20 min. Subsequently cells were 
incubated with formamide at 56 °C for 30 min. Then, blocking solution was added and cells were 
incubated with antibody mixture for 30 min. After washing with 1X washing buffer, cells were 
incubated with 100 µL of peroxidase substrate and absorbance was measured using an ELISA plate 
reader at 405 nm. The apoptotic positive control (single stranded DNA in PBS) was also included in 
the analysis. Data were expressed as percentage of cell apoptosis vs positive CTRL. 
3.2.5. TUNEL Assay 
To evaluate apoptosis also TUNEL assay was set up on P20 RS and RR-treated cells and P20 
CTRL cells grown on glass coverslips. Briefly, 10,000 cells were cultured O/N on sterile coverslip, 
previously coated with 0.1% gelatin. Then cells were fixed with 2% buffered formalin for 15 min at 
RT. After incubation with 0.2% Triton X-100 in PBS-Tween (PBST) for 15 min, coverslips were 
rinsed for 2 min in two changes of PBST. Then cells were blocked for endogenous peroxidase in 3% 
H2O2 in PBS for 10 min and after two washes in PBST, the TdT Reaction Buffer containing 1 mM 
cobalt chloride in 0.2 M sodium cacodylate, 25 mM Tris HCl and 0.25 mg/mL bovine serum albumin 
pH 6.6, was used in the pre-incubation at RT. Further the specimens were exposed to the TUNEL 
labeling mix, containing 400 U/µL calf thymus terminal deoxynucleotidyl transferase (TdT) (Roche 
Diagnostic, Monza, Italy) and 0.5 nmol Biotin-16-dUTP (Roche Diagnostic), in TdT reaction buffer 
followed by 1 h incubation in a moist chamber at 37 °C. The reaction was stopped with 300 mM NaCl, 
30 mM sodium citrate; the specimens were incubated with streptavidin-HRP (Sigma) in PBS for 20 min at 
RT. For light microscopy detection was performed with 3,3ʹ-diaminobenzidine tetrahydrochloride 
(DAB solution, Vector Laboratories, Burlingame, CA, USA) as chromogen; the specimens were 
counterstained with Gill’s hematoxylin, washed in running tap water, dehydrated by passing through 
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graded ethanol cleared in xylene and, finally, mounted with Diamount medium (Diapath, Martinengo, 
Italy). Cells distinctly stained with a clear positivity to TUNEL were observed under microscope 
(Leica DM750, Leica Microsystems, Milan, Italy) equipped with a Leica ICC50 HD camera. 
3.2.6. RNA Extraction and Adipogenesis PCR Array 
Before total RNA extraction treated and CTRL P20 cells were washed with cold 1X PBS. Total 
RNA extraction was performed with RNeasy kit with QIAzol Lysis Reagent (Qiagen, Milan, Italy), 
according to the manufacturer’s instructions. To perform PCR array, the cDNA was synthesised from 
the purified RNA samples according to RT2 First Strand kit (Qiagen). Briefly, 10 μL of genomic DNA 
elimination mixture including 1 μg of the purified RNA was incubated at 42 °C for 5 min. Then the 
mixture was immediately placed on ice for one minute and added with 20 μL of RT reaction mixture. 
Tubes were incubated at 42 °C for 15 min and at 95 °C for 5 min. Afterwards, 91 µL of RNase free 
H2O were added to each 30 µL of cDNA synthesis reaction. 
The expression profile of adipogenesis was performed using ready to use human Adipogenesis RT2 
Profiler PCR Array (PAHS-049Z; Qiagen) containing primers for 84 tested, five housekeeping genes 
and controls for RT and PCR reactions. The synthesized cDNA was used for preparation of reaction 
mixture according to the instructions of RT² SYBR® Green qPCR Mastermix kit (Qiagen,). Reaction 
mixture (20 µL), based on CFX96 Real-Time PCR Detection System (Bio-Rad, Milan, Italy), was 
added to 96 well-plate followed by thermal cycle recommended by manufacturer for Bio-Rad CFX96 
(10 min initial denaturation at 95 °C followed by 40 cycles: 15 s at 95 °C, 30 s amplification at 55 °C and 
30 s extension at 72 °C). Calculations of contamination with human genomic DNA accordingly to 
manufacturer instructions showed lack of contamination on all plates. Beta-2-microglobulin (B2M), 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), hypoxanthine phosphoribosyltransferase 1 
(HPRT1) and ribosomal protein L13a (RPL13A) were chosen from the group of five housekeeping 
genes as the best and least varying reference genes. β-Actin (ACTB) was not used, since the 
coefficient of variation of the Ct values was more than two fold than that of other housekeeping genes. 
The expression of target genes was normalized and ΔCts were calculated by the difference between Ct 
of target genes and the geometric mean of the four housekeeping genes. Differences between RR and 
RS samples and CTRL were calculated using the 2−ΔΔCt method [82,83], where 2−ΔΔCt represents the 
difference of a given target gene in treated cells vs CTRL. The n-fold expression of a given target gene 
was calculated as log2(2−ΔΔCt). 
3.3. Statistical Analysis 
Data were analysed with ANOVA [84]. For cell viability analysis, the model included the amount 
of RR or RS as fixed effect (4 levels). For apoptosis, triglyceride accumulation and lipolysis assays all 
models included the fixed effect of treatment (RR, RS and CTRL, 3 levels) and fixed effect of times of 
incubation that were for apoptosis assay 3 levels (P10, P20 and A7) for triglyceride and lipolysis 
assays 2 levels (P10 and P20) and their interactions. PCR array data, expressed as log2(n-fold), were 
analysed using one sample T test [84]. For a graphical appraisal and for quick identification of changes 
in PCR array log2(n-fold), Volcano plot was used and the statistical significance was reported as 
−Log(p-value) at p < 0.05. 
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4. Conclusions 
In conclusion, these data support the lipolytic and anti-adipogenetic activity of two different 
commercial extracts of Rhodiola rosea in primary human visceral pre-adipocytes during 
differentiation. In particular, the extract containing salidroside and rosavines (RR) was more effective 
in regulating the molecular and cellular events of adipogenesis, while RS extract, being richer in 
salidroside, induced lipolysis and the loss of differentiating cells by apoptosis. 
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